Acurx Pharmaceuticals to Discuss Q2 2026 Financial Results on August 14
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Source: PRnewswire
- Earnings Call Scheduled: Acurx Pharmaceuticals will hold a conference call on August 14, 2026, at 8:00 AM ET to discuss its Q2 2026 financial results, which is expected to positively impact the stock price by reflecting advancements in antibiotic development.
- Clinical Trial Progress: Ibezapolstat, the company's lead antibiotic candidate, is set to advance to international Phase 3 clinical trials targeting C. difficile infections, which, if successful, will significantly enhance the company's competitive position in the antibiotic market.
- FDA and EMA Approval: The company has received final agreement from both the FDA and EMA for the Phase 3 trials of Ibezapolstat, confirming study design elements and registration safety database requirements, laying the groundwork for future market applications and potentially accelerating drug approval processes.
- New Clinical Trial Initiation: Acurx has initiated a groundbreaking clinical trial for patients with multiply-recurrent CDI, with the first patient expected to enroll in Q4 this year; successful outcomes could shift treatment paradigms and strengthen the company's market position in antibiotics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACXP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACXP
Wall Street analysts forecast ACXP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.450
Low
30.00
Averages
30.50
High
31.00
Current: 1.450
Low
30.00
Averages
30.50
High
31.00
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acurx Pharmaceuticals to Discuss Q2 2026 Financial Results on August 14
- Earnings Call Scheduled: Acurx Pharmaceuticals will hold a conference call on August 14, 2026, at 8:00 AM ET to discuss its Q2 2026 financial results, which is expected to positively impact the stock price by reflecting advancements in antibiotic development.
- Clinical Trial Progress: Ibezapolstat, the company's lead antibiotic candidate, is set to advance to international Phase 3 clinical trials targeting C. difficile infections, which, if successful, will significantly enhance the company's competitive position in the antibiotic market.
- FDA and EMA Approval: The company has received final agreement from both the FDA and EMA for the Phase 3 trials of Ibezapolstat, confirming study design elements and registration safety database requirements, laying the groundwork for future market applications and potentially accelerating drug approval processes.
- New Clinical Trial Initiation: Acurx has initiated a groundbreaking clinical trial for patients with multiply-recurrent CDI, with the first patient expected to enroll in Q4 this year; successful outcomes could shift treatment paradigms and strengthen the company's market position in antibiotics.
See More
Acurx Pharmaceuticals Advances New Antibiotic to Phase 3 Trials
- Clinical Trial Advancement: Acurx Pharmaceuticals' lead antibiotic candidate, ibezapolstat, is set to enter international pivotal Phase 3 clinical trials targeting Clostridioides difficile infections, which is expected to significantly enhance treatment options for patients and address the growing crisis of antibiotic resistance.
- Structural Biology Insights: At the Leiden University Medical Center conference, Dr. Mia Urem presented high-resolution structural data showing ibezapolstat's binding to Gram+ bacterial DNA polymerase IIIC, indicating broad clinical utility across over 220 Gram+ species, thus providing a crucial foundation for the development of new antibiotics.
- Antibiotic R&D Pipeline: Acurx's pipeline includes antibiotic candidates targeting various resistant Gram+ bacteria, particularly methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, showcasing the company's strategic positioning to tackle significant public health challenges.
- Regulatory Support: Acurx has received positive regulatory guidance from the EMA, confirming that its clinical and non-clinical data support the Phase 3 program for ibezapolstat, which, if successful, will facilitate a Marketing Authorization Application in Europe, further solidifying its position in the antibiotic market.
See More
Acurx Pharmaceuticals Q1 Earnings: Launch of New Clinical Trial
- Clinical Trial Launch: On March 9, 2026, Acurx Pharmaceuticals announced the initiation of a clinical trial for ibezapolstat targeting recurrent C. difficile infections, aiming to simplify treatment from two agents to one, which could shift the treatment paradigm and enhance market competitiveness.
- Improved Financing: The company closed a registered direct offering of 825,085 shares at $3.03 per share on April 16, 2026, along with issuing short-term warrants for 1,650,170 shares at an exercise price of $2.78, thereby strengthening its liquidity position.
- Financial Performance: As of March 31, 2026, Acurx reported cash totaling $9.3 million, up from $7.6 million as of December 31, 2025, despite a net loss of $1.7 million or $0.62 per diluted share, indicating positive progress in financial management.
- FDA Guidance Update: Management noted that the FDA's new guidance allows for marketing approval for acute C. difficile with a single pivotal trial, and Acurx plans to discuss the applicability of this guidance with the FDA, potentially facilitating future clinical trial processes.
See More
Acurx Pharmaceuticals Q1 Financial Results Overview
- Financial Performance: Acurx Pharmaceuticals reported a Q1 GAAP EPS of -$0.62, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, the company had cash totaling $9.3 million, an increase from $7.6 million as of December 31, 2025, suggesting improvements in cash management.
- Funding Activities: During the quarter, Acurx raised approximately $3.1 million in gross proceeds through its Equity Line of Credit, providing essential funding for future R&D and operations.
- R&D Expense Trends: Research and development expenses for Q1 2026 were $0.3 million, down from $0.6 million in Q1 2025, primarily due to reductions in manufacturing and consulting costs, reflecting the company's efforts in cost control.
See More
Acurx Pharmaceuticals Reports Q1 2026 Financial Highlights
- Cash Position: As of March 31, 2026, Acurx reported cash totaling $9.3 million, a 17.6% increase from $7.6 million on December 31, 2025, indicating progress in financing efforts that bolster operational capacity.
- R&D Expense Reduction: The company incurred $0.3 million in R&D expenses for Q1 2026, a 50% decrease from $0.6 million in Q1 2025, primarily due to lower manufacturing and consulting costs, allowing for better resource allocation in future projects.
- Net Loss Improvement: Acurx reported a net loss of $1.7 million or $0.62 per share for Q1 2026, significantly down from a net loss of $2.1 million or $2.15 per share in Q1 2025, reflecting effective cost control measures.
- Clinical Trial Readiness: The lead antibiotic candidate Ibezapolstat has received final EMA and FDA agreement to advance into international Phase 3 clinical trials, setting a solid foundation for future market access and growth opportunities.
See More
Acurx Drug Shows Gut Microbiome Preservation Benefits
- Gut Microbiome Preservation: Acurx's DNA pol IIIC inhibitors presented at the 2026 ESCMID Congress demonstrate their ability to effectively preserve gut microbiome structure while treating resistant Gram-positive bacterial infections, significantly reducing complications associated with antibiotic-induced dysbiosis.
- Breakthrough in Antibiotic Development: Researchers highlighted that this novel antibiotic selectively targets systemic bacterial pathogens while sparing beneficial gut bacteria, marking a realization of the 'Holy Grail' in antibiotic development, which could transform treatment approaches for serious infections.
- New Research Funding: A new research grant from the Dutch government to Leiden University Medical Center and Acurx will facilitate further rational design of DNA pol IIIC inhibitors based on new structure-activity relationship data, expanding Acurx's R&D opportunities and anti-infective therapeutic portfolio.
- Clinical Application Prospects: Acurx's pipeline includes clinical applications targeting resistant bacteria like MRSA, expected to provide new treatment options for acute bacterial skin and skin structure infections, addressing the urgent market demand for novel antibiotics.
See More
Acurx Pharmaceuticals to Discuss Q2 2026 Financial Results on August 14
- Earnings Call Scheduled: Acurx Pharmaceuticals will hold a conference call on August 14, 2026, at 8:00 AM ET to discuss its Q2 2026 financial results, which is expected to positively impact the stock price by reflecting advancements in antibiotic development.
- Clinical Trial Progress: Ibezapolstat, the company's lead antibiotic candidate, is set to advance to international Phase 3 clinical trials targeting C. difficile infections, which, if successful, will significantly enhance the company's competitive position in the antibiotic market.
- FDA and EMA Approval: The company has received final agreement from both the FDA and EMA for the Phase 3 trials of Ibezapolstat, confirming study design elements and registration safety database requirements, laying the groundwork for future market applications and potentially accelerating drug approval processes.
- New Clinical Trial Initiation: Acurx has initiated a groundbreaking clinical trial for patients with multiply-recurrent CDI, with the first patient expected to enroll in Q4 this year; successful outcomes could shift treatment paradigms and strengthen the company's market position in antibiotics.
See More
Acurx Pharmaceuticals Advances New Antibiotic to Phase 3 Trials
- Clinical Trial Advancement: Acurx Pharmaceuticals' lead antibiotic candidate, ibezapolstat, is set to enter international pivotal Phase 3 clinical trials targeting Clostridioides difficile infections, which is expected to significantly enhance treatment options for patients and address the growing crisis of antibiotic resistance.
- Structural Biology Insights: At the Leiden University Medical Center conference, Dr. Mia Urem presented high-resolution structural data showing ibezapolstat's binding to Gram+ bacterial DNA polymerase IIIC, indicating broad clinical utility across over 220 Gram+ species, thus providing a crucial foundation for the development of new antibiotics.
- Antibiotic R&D Pipeline: Acurx's pipeline includes antibiotic candidates targeting various resistant Gram+ bacteria, particularly methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, showcasing the company's strategic positioning to tackle significant public health challenges.
- Regulatory Support: Acurx has received positive regulatory guidance from the EMA, confirming that its clinical and non-clinical data support the Phase 3 program for ibezapolstat, which, if successful, will facilitate a Marketing Authorization Application in Europe, further solidifying its position in the antibiotic market.
See More
Acurx Pharmaceuticals Q1 Earnings: Launch of New Clinical Trial
- Clinical Trial Launch: On March 9, 2026, Acurx Pharmaceuticals announced the initiation of a clinical trial for ibezapolstat targeting recurrent C. difficile infections, aiming to simplify treatment from two agents to one, which could shift the treatment paradigm and enhance market competitiveness.
- Improved Financing: The company closed a registered direct offering of 825,085 shares at $3.03 per share on April 16, 2026, along with issuing short-term warrants for 1,650,170 shares at an exercise price of $2.78, thereby strengthening its liquidity position.
- Financial Performance: As of March 31, 2026, Acurx reported cash totaling $9.3 million, up from $7.6 million as of December 31, 2025, despite a net loss of $1.7 million or $0.62 per diluted share, indicating positive progress in financial management.
- FDA Guidance Update: Management noted that the FDA's new guidance allows for marketing approval for acute C. difficile with a single pivotal trial, and Acurx plans to discuss the applicability of this guidance with the FDA, potentially facilitating future clinical trial processes.
See More
Acurx Pharmaceuticals Q1 Financial Results Overview
- Financial Performance: Acurx Pharmaceuticals reported a Q1 GAAP EPS of -$0.62, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, the company had cash totaling $9.3 million, an increase from $7.6 million as of December 31, 2025, suggesting improvements in cash management.
- Funding Activities: During the quarter, Acurx raised approximately $3.1 million in gross proceeds through its Equity Line of Credit, providing essential funding for future R&D and operations.
- R&D Expense Trends: Research and development expenses for Q1 2026 were $0.3 million, down from $0.6 million in Q1 2025, primarily due to reductions in manufacturing and consulting costs, reflecting the company's efforts in cost control.
See More
Acurx Pharmaceuticals Reports Q1 2026 Financial Highlights
- Cash Position: As of March 31, 2026, Acurx reported cash totaling $9.3 million, a 17.6% increase from $7.6 million on December 31, 2025, indicating progress in financing efforts that bolster operational capacity.
- R&D Expense Reduction: The company incurred $0.3 million in R&D expenses for Q1 2026, a 50% decrease from $0.6 million in Q1 2025, primarily due to lower manufacturing and consulting costs, allowing for better resource allocation in future projects.
- Net Loss Improvement: Acurx reported a net loss of $1.7 million or $0.62 per share for Q1 2026, significantly down from a net loss of $2.1 million or $2.15 per share in Q1 2025, reflecting effective cost control measures.
- Clinical Trial Readiness: The lead antibiotic candidate Ibezapolstat has received final EMA and FDA agreement to advance into international Phase 3 clinical trials, setting a solid foundation for future market access and growth opportunities.
See More
Acurx Drug Shows Gut Microbiome Preservation Benefits
- Gut Microbiome Preservation: Acurx's DNA pol IIIC inhibitors presented at the 2026 ESCMID Congress demonstrate their ability to effectively preserve gut microbiome structure while treating resistant Gram-positive bacterial infections, significantly reducing complications associated with antibiotic-induced dysbiosis.
- Breakthrough in Antibiotic Development: Researchers highlighted that this novel antibiotic selectively targets systemic bacterial pathogens while sparing beneficial gut bacteria, marking a realization of the 'Holy Grail' in antibiotic development, which could transform treatment approaches for serious infections.
- New Research Funding: A new research grant from the Dutch government to Leiden University Medical Center and Acurx will facilitate further rational design of DNA pol IIIC inhibitors based on new structure-activity relationship data, expanding Acurx's R&D opportunities and anti-infective therapeutic portfolio.
- Clinical Application Prospects: Acurx's pipeline includes clinical applications targeting resistant bacteria like MRSA, expected to provide new treatment options for acute bacterial skin and skin structure infections, addressing the urgent market demand for novel antibiotics.
See More
